Recombinant Anti-EGFR x Anti-MET Bispecific Antibody (scIgG) (SCIGG-154)

Recombinant Anti-EGFR x Anti-MET Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-EGFR and anti-MET IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Colorectal cancer; Pancreatic cancer; Head and neck cancer; Non-small cell lung cancer (NSCLC) therapy.

Datasheet INQUIRY

Specifications

Targets

EGFR & MET

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Colorectal cancer; Pancreatic cancer; Head and neck cancer; Non-small cell lung cancer (NSCLC)

Targets

Target 1

EGFR

Gene ID

1956

UniProt ID

P00533

Alternative Names

EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

Target 2

MET

Gene ID

4233

UniProt ID

A0A024R759

Alternative Names

MET; MET proto-oncogene, receptor tyrosine kinase; HGFR; AUTS9; RCCP2; c-Met; hepatocyte growth factor receptor; SF receptor; HGF receptor; HGF/SF receptor; proto-oncogene c-Met; scatter factor receptor; tyrosine-protein kinase Met; met proto-oncogene tyrosine kinase

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-EGFR x Anti-MET Bispecific Antibody (scIgG) (SCIGG-154). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-EGFR x Anti-MET Bispecific Antibody (scIgG) (CAT#: SCIGG-154)

Specifications

Targets

Customer Reviews and Q&As